TOKYO, Apr 3, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product […]

TOKYO, Apr 3, 2023 – (JCN Newswire via SEAPRWire.com) – TANAKA Holdings Co., Ltd. (Head office: Chiyoda-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), the pure holding company of TANAKA Group, announced today that it has formulated a diversity, equity, and inclusion (DE& […]